Table 4.
Occurrence of viral events, donor-specific antibodies, and acute rejections
| Intervention, n=31 | Control, n=33 | Total, n=64 | P Value | |
|---|---|---|---|---|
| Viral events | ||||
| CMV DNA ≥1000 copies per mla | 2 (6.5%) | 2 (6.1%) | 4 (6.3%) | >0.99 |
| ADV DNA ≥1000 copies per mla | 1 (3.3%) | 1 (3.0%) | 2 (3.1%) | >0.99 |
| HSV DNA ≥1000 copies per ml | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | — |
| EBV DNA ≥1000 copies per ml | 7 (22.6%) | 14 (42.4%) | 21 (32.8%) | 0.09 |
| BKPyVANa | 2 (6.5%) | 1 (3.0%) | 3 (4.7%) | 0.61 |
| Donor-specific antibodies | 8 (25.8%) | 9 (27.3) | 17 (26.6%) | 0.89 |
| No. of patients with ≥1 acute rejection (proven by biopsy of cause) | ||||
| Within 12 mo after transplantation | ||||
| Including borderline | 5 (16.1%) | 12 (36.4%) | 17 (26.6%) | 0.07 |
| Without borderline | 4 (12.9%) | 9 (27.3%) | 13 (20.3%) | 0.15 |
| Within 24 mo after transplantation | ||||
| Including borderline | 9 (29.0%) | 16 (48.5%) | 25 (39.1%) | 0.11 |
| Without borderline | 8 (25.8%) | 11 (33.3%) | 19 (29.7%) | 0.51 |
| All biopsies of cause: type of acute rejection episodes | ||||
| Borderline | 1 | 7 | 8 | |
| Banff type IA | 3 | 2 | 5 | |
| Banff type IB | 4 | 7 | 11 | |
| Banff type IIA | 3 | 1 | 4 | |
| Banff type IIB | 0 | 1 | 1 | |
| Banff type III | 0 | 1 | 1 |
—, not applicable; BKPyVAN, BK polyomavirus–associated nephropathy.
a
P values from Fisher exact tests.